This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy is a prescription treatment that requires evaluation by a licensed healthcare professional. Always consult a qualified clinician before starting any prescription medication.
If you've been hesitant about online TRT because of safety concerns — cardiovascular risk, prostate cancer fears, or just a general unease about getting prescribed hormones through a screen — the regulatory ground shifted under your feet in 2025. Twice. And most of the content ranking for “is online TRT safe” hasn't caught up yet.
Here's what actually happened, what it means, and how to evaluate a telehealth TRT platform now that the rules are changing.
February 2025: The Black Box Warning Comes Off
For years, every FDA-approved testosterone product carried a black box warning — the most serious warning category the agency uses — about an increased risk of heart attacks and strokes. That warning was based on observational studies and early trial signals that raised concern about cardiovascular safety in men using TRT.
Then the TRAVERSE trial reported its results. This wasn't a small study or a retrospective chart review — it was a prospective, randomized, placebo-controlled trial of over 5,200 hypogonadal men aged 45 to 80, specifically designed to answer the cardiovascular question. The finding: TRT did not increase the rate of major adverse cardiovascular events. The FDA reviewed the data and removed the black box warning from all testosterone product labeling in February 2025.
The agency didn't declare TRT risk-free. Updated labeling now includes a warning about potential blood pressure increases, and ambulatory blood pressure monitoring studies informed that addition. But the move from a black box warning to a standard precaution represents a fundamental recalibration of how the federal government views testosterone therapy's safety profile.
December 2025: The Expert Panel That Could Change Everything
Nine months after removing the cardiovascular warning, the FDA convened a 13-member expert panel — primarily urologists and federal health officials — to discuss TRT's regulatory framework from the ground up. The panel met on December 10, 2025, and its recommendations were sweeping.
The panel recommended expanding FDA-approved indications for testosterone therapy. Currently, TRT is only approved for men with low testosterone caused by specific pathological conditions — genetic disorders, pituitary tumors, testicular injury. The American Urological Association has long recommended a broader standard: testosterone therapy for any man with confirmed low levels and clinical symptoms, regardless of the cause. The panel urged the FDA to align its indications with the AUA's position, which would formally recognize age-related testosterone deficiency as a legitimate treatment indication.
Panel members also recommended removing the prostate cancer contraindication from product labeling. The TRAVERSE trial data showed no significant difference in prostate cancer incidence between TRT and placebo groups, and multiple panelists argued that the existing contraindication is not supported by contemporary evidence.
Perhaps most significantly, the panel raised the question of whether testosterone should remain a Schedule III controlled substance. The current classification — the same category as anabolic steroids, ketamine, and certain barbiturates — creates prescribing barriers, contributes to stigma, and adds regulatory overhead that panelists argued is no longer justified by the evidence. Reclassification would make TRT easier to prescribe and potentially less expensive to dispense.
The FDA followed up on December 11 with a formal Request for Information published in the Federal Register (Docket FDA-2025-N-6743), opening a public comment period that received over 2,000 submissions by the February 2026 deadline. As of April 2026, these remain recommendations — any labeling or scheduling changes will go through the FDA's standard review process. But the signal is clear.
What This Means for Men Evaluating Online TRT Platforms
The regulatory shift matters for two practical reasons. First, it validates the clinical foundation that online TRT platforms have been operating on — many telehealth providers have been treating age-related low testosterone for years under the AUA's broader guideline, even though the FDA's approved indication was narrower. The panel's recommendations, if adopted, would close that gap and reduce the legal ambiguity around online prescribing for symptomatic age-related decline.
Second, it raises the bar for what consumers should expect from their platform. When cardiovascular risk was the dominant concern, the conversation centered on “is TRT safe at all?” Now that question has largely been answered by TRAVERSE, the conversation should shift to “is this specific platform safe for me?” — which is a question about monitoring quality, clinician oversight, and operational transparency.
How to Evaluate a Telehealth TRT Platform for Safety
Not all online TRT providers are created equal, and the FDA's evolving position doesn't change what you should verify before trusting a platform with your hormonal health. Here's what to look for.
Three-entity structure disclosure. A legitimate platform clearly separates the technology company (which provides the app and coordination), the medical providers (independent licensed clinicians who exercise their own clinical judgment), and the pharmacy partners (who dispense medication). If you can't identify all three entities from the platform's terms of service or published materials, that's a concern. Platforms like Titan, Hims, and PeakPerforMAX all disclose this structure in their public documentation.
Comprehensive lab requirements. Any platform that prescribes TRT without requiring blood work first is operating outside clinical guidelines. You want a provider that orders a panel covering total testosterone, free testosterone, estradiol, PSA, CBC with hematocrit, and metabolic markers — and that requires follow-up labs at three to six months, not just at intake. Our guide to TRT side effects and monitoring covers what proper oversight looks like in detail.
Compounded medication disclosure. Most telehealth TRT platforms use compounded medications rather than commercially manufactured brand-name products. This is standard practice, but the platform should disclose it clearly: compounded medications are not FDA-approved as finished products. They're prepared by licensed pharmacies based on individual prescriptions, which is a well-established pharmaceutical practice — but you should know what you're receiving.
LegitScript or equivalent verification. LegitScript is an independent healthcare commerce verification service that reviews telehealth platforms for regulatory compliance. It's not a guarantee of quality, but it's a meaningful third-party check. Look for the badge on the platform's website and verify it independently at legitscript.com.
State availability transparency. Telehealth prescribing laws vary by state, and not every platform can serve every state. A platform that doesn't clearly disclose geographic limitations before you pay the intake fee is prioritizing conversion over transparency. Verify your state is covered before submitting personal health information or payment.
For men exploring this space, our comparison of men's health telehealth platforms evaluates several providers across these criteria. And if you're comparing specific platforms on cost, our 2026 TRT cost comparison breaks down what you're paying for at each price point.
What Hasn't Changed
The regulatory momentum is real, but TRT still requires clinical oversight. Prescription approval is never guaranteed. Contraindications still apply — prostate cancer, elevated hematocrit, untreated sleep apnea, and serious organ disease remain reasons for caution regardless of what the FDA panel recommended about labeling. Testosterone therapy still suppresses natural production through the negative feedback loop, still carries fertility implications, and still requires ongoing monitoring that doesn't end after the first prescription.
The biggest change isn't that TRT became safer — the TRAVERSE data suggests it was safer than the black box warning implied all along. The biggest change is that the medical establishment is catching up to the evidence, and the regulatory framework is likely to follow. For men who've been waiting for clearer signals before pursuing treatment, the signals don't get much clearer than a 13-member FDA expert panel saying it's time to modernize.
If you're ready to evaluate specific providers, start with our Titan TRT evaluation or our guide to understanding what testosterone replacement therapy means for men over 30.
MedicalFoundationOfNC.org Editorial Team — This article was prepared for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Regulatory information reflects the status of FDA proceedings as of April 2026 and is subject to change as the agency completes its review process. Consult a qualified healthcare professional before making any decisions about prescription medication.